Salvatore Ferragamo S.p.A. (SFRGF)

Inozyme Pharma Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	-	238.19	268.99	391.35	511.8	327.88
Short-Term Investments	-	50.41	35.28	10	-	0.28
Cash & Short-Term Investments	-	288.61	304.27	401.35	511.8	328.16
Cash Growth	-	-5.15%	-24.19%	-21.58%	55.96%	47.60%
Accounts Receivable	75.94	97.37	122.43	110.07	125.03	120.12
Other Receivables	-	33.64	39.74	37.85	35.33	22.72
Receivables	75.94	131.01	162.17	147.91	160.36	142.84
Inventory	309.11	307.89	298.35	275.32	274.57	341.64
Prepaid Expenses	-	7.62	7.3	9.04	9.77	13.11
Other Current Assets	0.06	24.09	16.73	15.53	8.48	14.71
Total Current Assets	385.1	759.21	788.81	849.15	964.97	840.45
Property, Plant & Equipment	638.84	734.19	817.3	671.29	686.9	658.36
Goodwill	6.68	6.68	6.68	6.68	6.68	6.68
Other Intangible Assets	28.22	10.46	13.33	13.2	12.32	13.78
Long-Term Deferred Tax Assets	-	145.14	122.35	109.09	105.47	119.66
Long-Term Deferred Charges	-	21.41	23.55	21.7	21.1	25.11
Other Long-Term Assets	123.28	23.76	40.92	49.18	51.61	49.92
Total Assets	1,182	1,701	1,813	1,720	1,849	1,714
Accounts Payable	141.38	162.8	172	172.59	180.75	134.09
Accrued Expenses	-	28.04	33.5	40.04	33.82	19.72
Current Portion of Long-Term Debt	-	116.14	81.41	30.36	76.12	60.4
Current Portion of Leases	-	124	114.44	106.59	110.01	103.51
Current Income Taxes Payable	-	19.26	12.69	25.22	25.73	25.97
Current Unearned Revenue	-	3.46	3.54	4.01	7.29	5.96
Other Current Liabilities	-49.5	25.78	22.65	45.31	30.17	15.13
Total Current Liabilities	91.88	479.47	440.23	424.11	463.89	364.78
Long-Term Debt	1,090	-	-	-	63.52	129.3
Long-Term Leases	611.67	552.34	596.6	468.74	487.23	464.4
Long-Term Deferred Tax Liabilities	-	5.68	6.83	6.07	3.38	6.94
Other Long-Term Liabilities	-1,210	37.24	40.15	38.38	36.19	26.97
Total Liabilities	584.16	1,081	1,091	944.88	1,063	1,004
Common Stock	596.79	16.88	16.88	16.88	16.88	16.88
Additional Paid-In Capital	-	3	3	3	3	3
Retained Earnings	-	655.56	740.92	782.77	776.03	696.09
Treasury Stock	-	-53.68	-56.22	-58.2	-15.53	-2.78
Comprehensive Income & Other	-	-2.67	16.6	7.37	-16.06	-19.61
Total Common Equity	596.79	619.09	721.17	751.81	764.31	693.58
Minority Interest	1.18	1	1	23.6	21.57	16.11
Shareholders' Equity	597.96	620.09	722.16	775.41	785.88	709.7
Total Liabilities & Equity	1,182	1,701	1,813	1,720	1,849	1,714
Total Debt	1,702	792.48	792.45	605.68	736.88	757.61
Net Cash (Debt)	-1,702	-503.87	-488.19	-204.33	-225.08	-429.45
Net Cash Per Share	-	-3.04	-2.95	-1.23	-1.34	-2.55
Filing Date Shares Outstanding	-	165.68	165.53	165.53	168.02	168.64
Total Common Shares Outstanding	-	165.68	165.53	165.41	168.02	168.64
Working Capital	293.22	279.74	348.58	425.04	501.08	475.67
Book Value Per Share	-	3.74	4.36	4.55	4.55	4.11
Tangible Book Value	561.89	601.95	701.16	731.93	745.31	673.12
Tangible Book Value Per Share	-	3.63	4.24	4.42	4.44	3.99
Land	-	28.33	29	29.61	29.37	29.14
Buildings	-	103.52	101.67	100.28	98.96	96.55
Machinery	-	213.05	199.53	189.36	182.57	188.02
Construction In Progress	-	20.83	18.51	8.3	7.95	5.66
Leasehold Improvements	-	315.03	298.25	293.63	290.76	264.08

Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.